Lilly to acquire Scorpion Therapeutics’ mutant-selective PI3Kα inhibitor program
Press Releases
January 13, 2025

Lilly to acquire Scorpion Therapeutics’ mutant-selective PI3Kα inhibitor program

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial

bradford

The Bradford Era

Local & Social